Could a blood extract save sight? early trial tests PRP for rare eye diseases

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥ 18 years. * Clinical diagnosis of retinitis pigmentosa (RP) or EMAP (Extensive Macular Atrophy with Pseudodrusen-like Appearance), confirmed by multimodal evaluation. * Best-corrected visual acuity (BCVA) ≥ counting fingers at 1 meter (approximately ≤ 1.9 logMAR) in the study eye. * Measurable visual field on iCare COMPASS (10-2 or 24-2) with acceptable reliability indices. * Clear ocular media adequate for safe intravitreal injection and high-quality optical coherence tomography (OCT) imaging. * Ability and willingness to provide written informed consent. * Ability to comply with scheduled study visits, including: * Baseline (M0) * Day 7-14 after injections * Month 2 (M2), Day 7-14 * Month 4 (M4), Day 7-14 * Month 6 (M6) * For ERG subset only: o Presence of a recordable baseline 30-Hz flicker electroretinogram (ERG) response, defined as a signal-to-noise ratio ≥ 3:1 and amplitude ≥ 3.0 μV. * Note: Absence of a measurable flicker ERG response does not exclude participation in the main study. Exclusion Criteria * Active ocular inflammation (anterior, intermediate, or posterior uveitis) or active infectious ocular disease in the study eye. * Active choroidal neovascularization or other macular diseases unrelated to RP or EMAP. * Uncontrolled glaucoma (intraocular pressure \> 21 mmHg despite therapy) or optic neuropathies not related to RP or EMAP. * Significant media opacity that may impair imaging quality or compromise the safety of intravitreal injection. * Recent ocular interventions that may confound study outcomes, including: * Intravitreal therapy within 3 months prior to enrollment. * Periocular corticosteroid injection within 3 months prior to enrollment. * Major intraocular surgery within 3 months prior to enrollment. * Known hypersensitivity to adalimumab, povidone-iodine, local anesthetics, or any component of the study formulations. * Coagulopathy or contraindications to ocular injections, including: * Platelet count \< 100,000/μL, or * INR \> 1.5 unless adequately corrected. * Pregnancy or breastfeeding. * Women of childbearing potential unwilling to use effective contraception during the study period. * Uncontrolled systemic disease that, in the investigator's judgment, increases risk or interferes with study participation or completion. * Participation in another interventional clinical trial within 3 months prior to enrollment.